Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
2022 events¹ (expected)
3
INNOVATION
✓ Achieved
NME Lead
Regulatory
H1
Pluvicto™ mCRPC (US/EU)
decisions
H1
VijoiceⓇ PROS (US)
H2
ScemblixⓇ 3L CML (JP/EU)
H2
tislelizumab ESCC 2L (US)
Readout not
supportive
× Missed
Other readouts
H1
sabatolimab HR-MDS Ph2
H1
CosentyxⓇ Lichen planus Ph2 PRELUDE
H1
CosentyxⓇ axSpA IV Ph3 INVIGORATE-1
H1
icenticaftor COPD Ph2b
Submissions
H1
H2
H1/H2 JakaviⓇ acute & chronic GVHD (EU /JP)
H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU/JP)
H1/H2 BeovuⓇ DME (US/EU ✓/JP)
ensovibep COVID-19 (US ✓)
H1/H2 Cosentyx® HS (EU/US)
H1/H2 tislelizumab NSCLC (EU/US)
tislelizumab 1L Nasopharyngeal cancer (US)
H2
UNR844 presbyopia Ph2 READER
Ph3/pivotal study
starts
H1
CosentyxⓇ peripheral SpA
H1
OAV101 SMA IT STEER ✔
H1
ensovibep COVID-19 (EMPATHY Part B)
H2
JDQ443 NSCLC mono
H2
ianalumab Sjögren's Syndrome
H2
ianalumab Lupus Nephritis
H2
CosentyxⓇ Psoriatic Arthritis IV (US)
H2
ociperlimab solid tumors
Submissions-
H2
canakinumab NSCLC Ph3 Canopy A
H2
TM
Pluvicto nmCRPC
enabling
H2
iptacopan PNH Ph3 APPLY-PNH
H2
YTB323 2L DLBCL
readouts
H2
KisqaliⓇ HR+/HER2- BC (adj) Ph3 NATALEE (event driven
now moving to 2023)
H2
OAV101 SMA IT Ph3b STRENGTH
H2
lutetium (177Lu) vipivotide tetraxetan mCRPC1, pre-taxane
Ph3 PSMAfore²
1. Selected. 2. Could move to early 2023.
20 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation